ライフサイエンスコーパス: sevelamer

1 rol reduction caused by statins and possibly sevelamer.

2 with NAFLD as well as in those treated with sevelamer.

3 3 by CaCO(3) and decreased even further with sevelamer (16.4 +/- 8.9, P < 0.02 versus CaCO(3)).

4 in contrast, values remained unchanged with sevelamer (9.6 +/- 01 versus 8.9 +/- 0.2 mg/dl; P < 0.00

5 Sevelamer, a nonabsorbable hydrogel, is as efficacious a

6 Furthermore, sevelamer administration reduced coagulation biomarkers,

7 Sevelamer also exhibits beneficial effects on lipids, co

8 We also analyzed how sevelamer alters inflammation and bile acid signaling in

9 rimental model of CRF, these studies compare sevelamer and calcium carbonate (CaCO(3)) in the control

10 In a head-to-head randomized clinical trial, sevelamer and calcium-based binders achieved similarly e

11 In a randomized clinical trial comparing sevelamer and calcium-based phosphate binders, treatment

12 lar in subjects randomly assigned to receive sevelamer and calcium-based phosphate binders.

13 tatistically significant differences between sevelamer and placebo with regard to LV mass, systolic a

14 ; in this compliant subgroup, treatment with sevelamer associated with lower urinary phosphate excret

15 se report, we explore the unique features of sevelamer-associated recto-sigmoid ulcers which led to h

16 ary artery and aortic calcification, whereas sevelamer attenuated or arrested progression.

17 Sevelamer, besides normalizing the serum phosphorus, sur

18 bjects were randomized (292 to FC and 149 to sevelamer carbonate and/or calcium acetate [active contr

19 t2b-deficient mice with the phosphate binder sevelamer carbonate further reduced serum phosphate leve

20 n, this study does not provide evidence that sevelamer carbonate improves LV mass, LV function, or ar

21 ng diabetic and uremic vasculopathy and that sevelamer carbonate may be capable of increasing bone fo

22 duction of established VC by the addition of sevelamer carbonate to the diets of this murine metaboli

23 (2) to calcium acetate, lanthanum carbonate, sevelamer carbonate, or placebo.

24 iod, during which time all patients received sevelamer carbonate, we randomly assigned 109 patients t

25 However, sevelamer caused a dramatic reduction of renal Ca deposi

26 eral apposition in Npt2b-deficient mice, but sevelamer did not affect bone formation and rate of mine

27 Thus, in this study population, sevelamer did not reduce microbial translocation but may

28 Sevelamer did not significantly change markers of microb

29 e had been treated with the phosphate binder sevelamer for two months.

30 /- 164 pg/ml (P < 0.01) in the CaCO3 and the sevelamer groups, respectively (NS between groups).

31 calcium-containing phosphate binders such as sevelamer have been recommended to reduce cardiovascular

32 Sevelamer, however, maintained serum calcium concentrati

33 calcium- and aluminum-free phosphate binder, sevelamer hydrochloride (RenaGel), reduces serum P witho

34 Sevelamer hydrochloride is an exchange resin and was not

35 In a mouse model of NAFLD, sevelamer improved disease and counteracted innate immun

36 hich may cause inflammation, is decreased by sevelamer in patients undergoing hemodialysis.

37 In this study, we assessed the efficacy of sevelamer in treating mice with non-alcoholic fatty live

38 Sevelamer is a nonabsorbed hydrogel that binds phosphoru

39 despite a similar control of serum P and SH, sevelamer is more effective than CaCO(3) in preventing r

40 Sevelamer is widely used in chronic kidney disease and e

41 These results suggest that sevelamer may have important actions in decreasing diabe

42 ort-term and open-label studies suggest that sevelamer might lower the concentration of uric acid, an

43 To what extent the phosphate binder sevelamer modulates these effects is not well understood

44 were randomly assigned to CaCO3 (n = 14) or sevelamer (n = 15), concomitant with either intermittent

45 bonate, we randomly assigned 109 patients to sevelamer (n=55) or placebo (n=54) for an additional 36

46 sis were randomly assigned to receive either sevelamer or calcium-based phosphorus binders in an inte

47 rn diet for 12 weeks followed by a diet-plus-sevelamer regimen for 2 or 12 weeks.

48 .1 and 5.6 +/- 0.3 mg/dl (NS) with CaCO3 and sevelamer, respectively.

49 Thus, treatment with either CaCO3 or sevelamer resulted in equivalent control of the biochemi

50 reexamined, and the potential advantages of sevelamer should be considered when selecting a primary

51 urnover renal osteodystrophy; treatment with sevelamer significantly decreased the number of osteocla

52 Sevelamer therapy increased osteoblast surfaces in the m

53 tudy, we evaluated the effects of 8 weeks of sevelamer therapy on 36 HIV-infected subjects who were n

54 Sevelamer-treated NAFLD livers had notably fewer pro-inf

55 nd of the study) was significantly larger in sevelamer-treated subjects (-0.64 mg/dl versus -0.26 mg/

56 Twenty-three percent of sevelamer-treated subjects experienced a study-related r

57 Sevelamer treatment controlled serum P independent of in

58 Sevelamer treatment significantly reduced liver steatosi

59 During sevelamer treatment, however, levels of soluble tissue f

60 stine of NAFLD mice that was counteracted by sevelamer treatment.

61 (U-HP); UHP + 3% CaCO(3) (U-HP+C); UHP + 3% sevelamer (U-HP+S).

62 Sevelamer was as effective as CaCO(3) in the control of

63 cium-based phosphate binders, treatment with sevelamer was associated with a significant reduction in

64 The phosphorus binder sevelamer was developed to overcome the limitations asso

65 In addition, sevelamer was found to be effective in decreasing serum

66 The effects of calcium carbonate (CaCO3) and sevelamer were compared in pediatric peritoneal dialysis

67 IV-infected pigtailed macaques with the drug sevelamer, which binds microbial lipopolysaccharide in t

68 g-term, randomized, clinical trial comparing sevelamer with calcium-based phosphate binders.

69 this recently-reported entity in patients on sevelamer with suggestive symptoms, as this medication i

70 in serum uric acid concentration induced by sevelamer would be confirmed in a long-term, randomized,